Squarepoint’s MoonLake Immunotherapeutics MLTX Stock Holding History

Squarepoint’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.05M	Sell	110,217 -11,423	-9%	-$189K	﹤0.01%	2161
2025 Q4	$1.6M	Buy	121,640 +90,950	+296%	+$1.07M	﹤0.01%	2212
2025 Q3	$220K	Buy	30,690 +13,119	+75%	+$684K	﹤0.01%	3881
2025 Q2	$829K	Buy	17,571 +629	+4%	+$25.6K	﹤0.01%	2828
2025 Q1	$662K	Buy	+16,942	New	+$730K	﹤0.01%	3033
2024 Q4	–	Sell	-6,402	Closed	-$327K	–	5332
2024 Q3	$323K	Sell	6,402 -938	-13%	-$44K	﹤0.01%	3394
2024 Q2	$323K	Buy	+7,340	New	+$311K	﹤0.01%	3388
2024 Q1	–	Sell	-18,903	Closed	-$1.14M	–	4370
2023 Q4	$1.14M	Buy	18,903 +4,994	+36%	+$257K	﹤0.01%	2429
2023 Q3	$793K	Sell	13,909 -27,522	-66%	-$1.52M	﹤0.01%	2481
2023 Q2	$2.11M	Buy	+41,431	New	+$1.11M	0.01%	1627

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Squarepoint's MLTX Position: Q1 2026 in Review

Squarepoint reduced its MoonLake Immunotherapeutics (MLTX) stake by 9.4% in Q1 2026, selling an estimated $189K and leaving 110,217 shares worth $2.05M. The position accounts for ﹤0.01% of the portfolio, ranked #2161.

Squarepoint first reported a position in MLTX in Q2 2023 and has held it in 10 quarters since. The position peaked at $2.11M in Q2 2023. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Squarepoint held 110,217 shares of MoonLake Immunotherapeutics worth $2.05M as of Q1 2026.
Squarepoint sold 11,423 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $189K.
MoonLake Immunotherapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2161 holding.
Squarepoint first reported a position in MoonLake Immunotherapeutics in Q2 2023 and has held it in 10 quarters since.
Squarepoint's MoonLake Immunotherapeutics position peaked at $2.11M in Q2 2023.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.